KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Raw Materials (2016)

AbbVie (ABBV) has disclosed Raw Materials for 5 consecutive years, with $132.0 million as the latest value for Q2 2016.

  • On a quarterly basis, Raw Materials rose 4.76% to $132.0 million in Q2 2016 year-over-year; TTM through Jun 2016 was $132.0 million, a 4.76% increase, with the full-year FY2015 number at $169.0 million, up 9.74% from a year prior.
  • Raw Materials was $132.0 million for Q2 2016 at AbbVie, down from $155.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $261.0 million in Q4 2013 to a low of $126.0 million in Q2 2015.
  • A 5-year average of $188.2 million and a median of $163.0 million in 2015 define the central range for Raw Materials.
  • Biggest YoY gain for Raw Materials was 9.74% in 2015; the steepest drop was 45.02% in 2015.
  • AbbVie's Raw Materials stood at $258.0 million in 2012, then grew by 1.16% to $261.0 million in 2013, then crashed by 41.0% to $154.0 million in 2014, then rose by 9.74% to $169.0 million in 2015, then dropped by 21.89% to $132.0 million in 2016.
  • Per Business Quant, the three most recent readings for ABBV's Raw Materials are $132.0 million (Q2 2016), $155.0 million (Q1 2016), and $169.0 million (Q4 2015).